Creatine monohydrate supplementation does not increase muscle strength, lean body mass, or muscle phosphocreatine in patients with myotonic dystrophy type 1
Tarnopolsky M, Mahoney D, Thompson T, Naylor H, Doherty TJ
Muscle & nerve · 44 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2003-11-21 · Muscle Nerve · vol. 29 · número 1 · págs. 51–58
- Editorial
- Wiley
- Citado
- 71 citas · más que el 81% de estudios similares · 1.7× el promedio de su campo
- Referencias
- 54 trabajos
- Acceso
- De pago
- Áreas de investigación
- Muscle metabolism and nutrition · Muscle Physiology and Disorders · Genetic Neurodegenerative Diseases
- Palabras clave
- creatine monohydrate supplementation, myotonic dystrophy type 1, muscle strength, lean body mass, creatine kinase, serum creatinine, activities of daily living, forearm flexor muscles, isometric strength
- MeSH
- muscle, skeletal, humans, muscle weakness, myotonic dystrophy, creatine, phosphocreatine, muscle proteins, respiratory function tests, body mass index, treatment failure, activities of daily living, magnetic resonance spectroscopy, cross-over studies, exercise tolerance, adult, middle aged, female, male
5 autores
- Mark Andrew Tarnopolsky🇨🇦 · autor de correspondenciaMcMaster University
- Douglas J. Mahoney🇨🇦McMaster University
- Terry Thompson🇨🇦Western University
- Heather K Naylor🇨🇦McMaster University
- Timothy J. Doherty🇨🇦Western University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Creatine monohydrate (CrM) supplementation may increase strength in some types of muscular dystrophy. A recent study in myotonic muscular dystrophy type 1 (DM1) did not find a significant treatment effect, but measurements of muscle phosphocreatine (PCr) were not performed. We completed a randomized, double-blind, cross-over trial using 34 genetically confirmed adult DM1 patients without significant cognitive impairment. Participants received CrM (5 g, approximately 0.074 g/kg daily) and a placebo for each 4-month phase with a 6-week wash-out. Spirometry, manual muscle testing, quantitative isometric strength testing of handgrip, foot dorsiflexion, and knee extension, handgrip and foot dorsiflexion endurance, functional tasks, activity of daily living scales, body composition (total, bone, and fat-free mass), serum creatine kinase activity, serum creatinine concentration and clearance, and liver function tests were completed before and after each intervention, and muscle PCr/beta-adenosine triphosphate (ATP) ratios of the forearm flexor muscles were completed at the end of each phase. CrM supplementation did not increase any of the outcome measurements except for plasma creatinine concentration (but not creatinine clearance). Thus, CrM supplementation at 5 g daily does not have any effects on muscle strength, body composition, or activities of daily living in patients with DM1, perhaps because of a failure of the supplementation to increase muscle PCr/beta-ATP content.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.